Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

systematic literature reviews

- PMLiVE

Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market

Authored by: Marc Garcia and Tania Rodrigues

Research Partnership

EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech

Maria Dimitrova (Consultant – HTA) and Samantha Gillard (Director – HTA) provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device...

Mtech Access

- PMLiVE

Market access and reimbursement in key European markets

An introductory guide to European market access and reimbursement stakeholders and processes in France, Great Britain, Germany, Italy and Spain.

Mtech Access

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

RPR: an agile, on-demand platform that provides clients with faster, higher-quality insights via direct, automated stakeholder engagement.

Genesis Research Group

Accelerating Generation of Payer Insights & Evidence Across the Lifecycle to Achieve Optimal Access

Genesis Research Group

ISPOR Europe: Generating Payer Insights & Evidence: Meeting the Challenges of New Evidence Paradigm

Genesis Research Group

Accelerating Generation of Payer Insights & Evidence Across the Lifecycle to Achieve Optimal Access

Genesis Research Group

- PMLiVE

FDA establishes new advisory committee to provide expertise on digital health

The committee will consist of individuals with technical and scientific expertise from diverse disciplines and backgrounds

- PMLiVE

Sanofi partners with AI specialist BioMap in deal worth more than $1bn

The strategic collaboration is aimed at accelerating drug discovery for biotherapeutics

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links